6 news items
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
MILESTONES
Report pivotal complete response
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
ACB
ACRV
AMD
9 Apr 24
. (NASDAQ:KA) fell 17.1% to $0.4490. Kineta reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA-101 clinical trial
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
a 100% CR/CRi (complete response/complete response with incomplete hematologic recovery) rate in response-evaluable patients (nine of nine) treated
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
Report pivotal complete response (CR) data from the SELECT-MDS-1 Phase 3
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
SYRS
25 Mar 24
overexpression. This initial cohort of 190 patients is necessary to support the complete response (CR) primary endpoint analysis. Syros expects to report these pivotal data by the middle of the fourth quarter of 2024.
0gfrsd912s6g9w9i98jz a8j89442
SYRS
25 Mar 24
-- On track to report pivotal complete response
- Prev
- 1
- Next